456 related articles for article (PubMed ID: 17919259)
1. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
Ali F; Raufi MA; Washington B; Ghali JK
Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin-receptor antagonists.
Hoorn EJ; Zietse R
Future Cardiol; 2010 Jul; 6(4):523-34. PubMed ID: 20608824
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic use of vaptans for the treatment of dilutional hyponatremia.
Cassagnol M; Shogbon AO; Saad M
J Pharm Pract; 2011 Aug; 24(4):391-9. PubMed ID: 21813818
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
6. Conivaptan Yamanouchi.
Doggrell SA
Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
[TBL] [Abstract][Full Text] [Related]
7. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
Schwarz ER; Sanghi P
Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
Goldsmith SR; Elkayam U; Haught WH; Barve A; He W
J Card Fail; 2008 Oct; 14(8):641-7. PubMed ID: 18926434
[TBL] [Abstract][Full Text] [Related]
9. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
10. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Yamamura Y; Nakamura S; Itoh S; Hirano T; Onogawa T; Yamashita T; Yamada Y; Tsujimae K; Aoyama M; Kotosai K; Ogawa H; Yamashita H; Kondo K; Tominaga M; Tsujimoto G; Mori T
J Pharmacol Exp Ther; 1998 Dec; 287(3):860-7. PubMed ID: 9864265
[TBL] [Abstract][Full Text] [Related]
11. Conivaptan: promise of treatment in heart failure.
Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
[TBL] [Abstract][Full Text] [Related]
12. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
Patel GP; Balk RA
Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
Nemerovski C; Hutchinson DJ
Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
[TBL] [Abstract][Full Text] [Related]
14. [Vasopressin receptor antagonists: the vaptans].
Villabona C
Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
[TBL] [Abstract][Full Text] [Related]
15. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
[TBL] [Abstract][Full Text] [Related]
16. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Palm C; Pistrosch F; Herbrig K; Gross P
Am J Med; 2006 Jul; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
[TBL] [Abstract][Full Text] [Related]
17. A novel vasopressin dual V1A/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Wada K; Matsukawa U; Fujimori A; Arai Y; Sudoh K; Sasamata M; Miyata K
Biol Pharm Bull; 2007 Jan; 30(1):91-5. PubMed ID: 17202666
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
19. Is there a cardiovascular rationale for the use of combined vasopressin V1a/V2 receptor antagonists?
Goldsmith SR
Am J Med; 2006 Jul; 119(7 Suppl 1):S93-6. PubMed ID: 16843092
[TBL] [Abstract][Full Text] [Related]
20. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
